Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Robert Klamroth, Jerzy Windyga, Vlad Radulescu, Peter W. Collins, Oleksandra Stasyshyn, Hishamshah Mohd Ibrahim, Werner Engl, Srilatha D. Tangada, William Savage, Bruce Ewenstein

Blood (2021) 137 (13): 1818–1827.

https://doi.org/10.1182/blood.2020005673

Published: 2021

Includes: Supplemental data

Journal Articles

Occupy BTK: the key to controlling CLL

Philip A. Thompson

Blood (2020) 136 (1): 4–6.

https://doi.org/10.1182/blood.2020005877

Published: 2020

Journal Articles

The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells

Eric Robert Fedyk, BSc, MSc, PhD, Neeraja Idamakanti, BVSc MSc DVM, Jia Chen, BSc, MSc, PhD, Jose Estevam, BSc MSc, Vivian Hernandez, BSc PhD, Matthew Wagoner, BSc PhD, Mary Carsillo, BSc DVM PhD, Deborah Berg, RN, MSN, Kristina Allikmets, MD PhD, Gezim Lahu, BSc MSc PhD, Antonio Palumbo, MD

Blood (2019) 134 (Supplement_1): 3136.

https://doi.org/10.1182/blood-2019-128238

Published: 2019

Journal Articles

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

Blood (2019) 134 (Supplement_1): 4150.

https://doi.org/10.1182/blood-2019-127619

Published: 2019

Journal Articles

Pilot Study of Oral Realgar-Indigo Naturalis Formula in Pediatric Acute Promyelocyticleukemia: Effectiveness and Population Pharmacokinetics

Li Zhang, Xin-mei Yang, Jing Chen, Lei Hu, Fan Yang, Yue Zhou, Bei-bei Zhao, Wei Zhao, Xiao-fan Zhu, PhD

Blood (2019) 134 (Supplement_1): 5084.

https://doi.org/10.1182/blood-2019-122876

Published: 2019

Journal Articles

Exposure-Response of Quizartinib Efficacy in Patients with Relapsed/Refractory AML

Dongwoo Kang, PhD, Julie Passarell, MA, Malaz A Abutarif, PhD, Jeanne Mendell, PhD MPH, Ophelia Yin, PhD

Blood (2019) 134 (Supplement_1): 1263.

https://doi.org/10.1182/blood-2019-122582

Published: 2019

Journal Articles

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

Jennifer Woyach, MD, Deborah M. Stephens, DO, Ian W. Flinn, MD PhD, Seema A. Bhat, MD, Ronald E. Savage, Feng Chai, MD, Sudharshan Eathiraj, PhD, Lindsey Granlund, Lyndsey A. Szuszkiewicz, Brian Schwartz, MD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4298.

https://doi.org/10.1182/blood-2019-127260

Published: 2019

Journal Articles

Myeloma Cells Have the Ability to Suppress Th1-Inducing Capacity but Enhance Th2-Mediated Response of Dendritic Cells By Producing Factors Other Than Soluble SLAMF7

Yoshiko Azuma, MD, Tomoki Ito, MD PhD, Muneo Inaba, PhD, Kai Imai, MD, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Atsushi Satake, MD PhD, Kazuyoshi Ishii, MDMPH,PhD, Shosaku Nomura, MD PhD

Blood (2018) 132 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2018-99-113282

Published: 2018

Journal Articles

Beyond ABR: High FIX Activity Levels Translate into Clinical Benefits over Standard Prophylaxis

Guy Young, Manuel Carcao, MDMSc, Susan Kearney, MD, Stephanie Valer Seremetis, MD, David L Cooper, MD

Blood (2017) 130 (Supplement 1): 2372.

https://doi.org/10.1182/blood.V130.Suppl_1.2372.2372

Published: 2017

Journal Articles

Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentor™2 Trial

Manuel Carcao, Carmen Altisent, PhD, Giancarlo Castaman, Katsuyuki Fukutake, MD PhD, Aida Inbal, MD, Bryce A. Kerlin, Craig M. Kessler, MD, Riitta Lassila, MD PhD, Johannes Oldenburg, Prof, Anders Rosholm, May-Lill Garly, MD PhD, Diane J. Nugent, MD

Blood (2016) 128 (22): 2573.

https://doi.org/10.1182/blood.V128.22.2573.2573

Published: 2016

Journal Articles

Serial Trough Anti-Xa Levels to Assess Low Molecular Weight Heparin Accumulation in Patients with Chronic Kidney Disease: Analysis of Crcl <30 Ml/Min from the Trivet Study

Wendy Lim, MD, Mark Crowther, MD, Luqi Wang, James D. Douketis, MD, Terri Schnurr, Cathy Moreau, Catherine Clase, Marc Rodger, MD MSc, FRCPC, Erik Yeo, MD, Martine Leblanc, Philip McFarlane, Christine M. Ribic, MD

Blood (2016) 128 (22): 90.

https://doi.org/10.1182/blood.V128.22.90.90

Published: 2016

Journal Articles

PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis

Matthew J Carter, PhD, Kerry L Cox, Stuart J Blakemore, Anna H Turaj, MSc, Robert J Oldham, Lekh N. Dahal, PhD, Stacey Tannheimer, Francesco Forconi, MD DM, PhD FRCPath, Graham Packham, PhD, Mark S Cragg, PhD

Blood (2016) 128 (22): 3241.

https://doi.org/10.1182/blood.V128.22.3241.3241

Published: 2016

Journal Articles

Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients

Robert Klamroth, Toshko Lissitchkov, MD, Luminita Rusen, Olaf Walter, MD MBA, Johann Bichler, PhD, K John Pasi, Andreas Tiede, MD PhD, Sigurd Knaub, PhD

Blood (2015) 126 (23): 547.

https://doi.org/10.1182/blood.V126.23.547.547

Published: 2015

Journal Articles

Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies

Paul A Hamlin, Jr., MD, Ian Flinn, MD, Nina wagner-Johnston, MD, Jan A Burger, MD PhD, Glenn Michelson, MD, Anjali Pandey, PhD, Matt Birrell, Greg P. Coffey, PhD, Janet M Leeds, PhD, John T. Curnutte, MDPhD, Manish R. Patel, MD

Blood (2015) 126 (23): 3929.

https://doi.org/10.1182/blood.V126.23.3929.3929

Published: 2015

Journal Articles

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

John Carl Panetta, Sharyn D Baker, PharmD, PhD, Hagop M. Kantarjian, MD, Clinton Stewart, Pharm.D., Blake Pond, MS, Meghan Macaraeg, BS, Tolu Makinde, PhD, Sheetal Vali, PhD, Naval Daver, MD, Abhijit Ramachandran, MS, Robert Collins, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3695.

https://doi.org/10.1182/blood.V126.23.3695.3695

Published: 2015

Journal Articles

Activity of OTX015 (MK-8628), a BET-Bromodomain Inhibitor, in Acute Myeloid Leukemia (AML) Progenitor Cells

Louise Roulin, Ashfaq Ali, Aline Masse, Marie-Magdelaine Coudé, Dominique Bluteau, Thorsten Braun, MD PhD, Jeannig Berrou, Olivier Bluteau, Marc Delord, Maria Eugenia Riveiro, Patrice EDOUARD Herait, MD, Jean Soulier, MD PhD, André Baruchel, MD, Claude Gardin, MD, Hervé Dombret, Raphaël Itzykson, MD PhD

Blood (2015) 126 (23): 2588.

https://doi.org/10.1182/blood.V126.23.2588.2588

Published: 2015

Journal Articles

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Gerald Spotts, PhD, Steven W. Pipe, MD, Erik Berntorp, MD PhD, Peter W. Collins, MD, Victor S. Blanchette, MD FRCPC, Kathelijn Fischer, MD PhD MSC, MyungShin Oh, Leonard A. Valentino, MD FAAP

Blood (2014) 124 (21): 689.

https://doi.org/10.1182/blood.V124.21.689.689

Published: 2014

Journal Articles

ONO-4059—a Potent and Selective Reversible Bruton’s Tyrosine Kinase (Btk) Inhibitor: Single Agent, Twice Daily (BD) Dosing and Dosing with Food Results in Sustained, High Trough Levels of ONO-4059, Translating into 100% Tumour Remission in a TMD-8 Xenograft Model

Toshio Yoshizawa, Tomoko Yasuhiro, Hideyuki Honda, Kazuhito Kawabata, PhD

Blood (2014) 124 (21): 4502.

https://doi.org/10.1182/blood.V124.21.4502.4502

Published: 2014

Journal Articles

New Data on the Safety and Efficacy of Recombinant FXIII in Patients with Congenital FXIII A-Subunit Deficiency

Katsuyuki Fukutake, MD PhD, Manual Carcao, MD, Aida Inbal, MD, Bryce A. Kerlin, MD, Johannes Oldenburg, MD PhD, Anders Rosholm, MSc, PhD, May-Lill Garly, MD PhD, Diane J. Nugent, MD

Blood (2014) 124 (21): 1520.

https://doi.org/10.1182/blood.V124.21.1520.1520

Published: 2014

Journal Articles

Long-Term Outcomes Of a Small Cohort At a Single Canadian Centre Of Severe Subunit A FXIII Deficient Patients (F13A1: c.691-1G>A) Treated Prophylactically With Fibrogammin P

Andrew P Sullivan, Jill MacDonald, Charlotte Sheppard, Mary-Frances Scully, MRCP, FRCP

Blood (2013) 122 (21): 2360.

https://doi.org/10.1182/blood.V122.21.2360.2360

Published: 2013

NARROW

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Occupy BTK: the key to controlling CLL

The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

Pilot Study of Oral Realgar-Indigo Naturalis Formula in Pediatric Acute Promyelocyticleukemia: Effectiveness and Population Pharmacokinetics

Exposure-Response of Quizartinib Efficacy in Patients with Relapsed/Refractory AML

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

Myeloma Cells Have the Ability to Suppress Th1-Inducing Capacity but Enhance Th2-Mediated Response of Dendritic Cells By Producing Factors Other Than Soluble SLAMF7

Beyond ABR: High FIX Activity Levels Translate into Clinical Benefits over Standard Prophylaxis

Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentor™2 Trial

Serial Trough Anti-Xa Levels to Assess Low Molecular Weight Heparin Accumulation in Patients with Chronic Kidney Disease: Analysis of Crcl <30 Ml/Min from the Trivet Study

PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis

Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients

Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

Activity of OTX015 (MK-8628), a BET-Bromodomain Inhibitor, in Acute Myeloid Leukemia (AML) Progenitor Cells

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

ONO-4059—a Potent and Selective Reversible Bruton’s Tyrosine Kinase (Btk) Inhibitor: Single Agent, Twice Daily (BD) Dosing and Dosing with Food Results in Sustained, High Trough Levels of ONO-4059, Translating into 100% Tumour Remission in a TMD-8 Xenograft Model

New Data on the Safety and Efficacy of Recombinant FXIII in Patients with Congenital FXIII A-Subunit Deficiency

Long-Term Outcomes Of a Small Cohort At a Single Canadian Centre Of Severe Subunit A FXIII Deficient Patients (F13A1: c.691-1G>A) Treated Prophylactically With Fibrogammin P

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only